Randall Stanicky
Stock Analyst at RBC Capital
(2.34)
# 2,407
Out of 4,791 analysts
32
Total ratings
60%
Success rate
5.18%
Average return
Main Sectors:
Stocks Rated by Randall Stanicky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Outperform | $129 → $135 | $205.19 | -34.21% | 10 | Feb 4, 2021 | |
| PRGO Perrigo Company | Downgrades: Sector Perform | $59 → $49 | $27.91 | +75.56% | 8 | Jan 6, 2021 | |
| PFE Pfizer | Downgrades: Sector Perform | $43 → $42 | $24.70 | +70.04% | 3 | Dec 16, 2020 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $170 → $180 | $126.44 | +42.36% | 2 | Nov 3, 2020 | |
| MRK Merck & Co. | Maintains: Sector Perform | $92 → $89 | $86.60 | +2.77% | 1 | Apr 1, 2020 | |
| AMRX Amneal Pharmaceuticals | Maintains: Sector Perform | $3 → $4 | $8.17 | -51.04% | 3 | Jan 2, 2020 | |
| OPTN OptiNose | Initiates: Outperform | $495 | $9.16 | +5,303.93% | 1 | Nov 7, 2017 | |
| TEVA Teva Pharmaceutical Industries | Downgrades: Underperform | n/a | $15.29 | - | 3 | Aug 4, 2017 | |
| PCRX Pacira BioSciences | Initiates: Outperform | $58 | $24.89 | +133.03% | 1 | Apr 13, 2017 | |
AbbVie
Feb 4, 2021
Maintains: Outperform
Price Target: $129 → $135
Current: $205.19
Upside: -34.21%
Perrigo Company
Jan 6, 2021
Downgrades: Sector Perform
Price Target: $59 → $49
Current: $27.91
Upside: +75.56%
Pfizer
Dec 16, 2020
Downgrades: Sector Perform
Price Target: $43 → $42
Current: $24.70
Upside: +70.04%
Jazz Pharmaceuticals
Nov 3, 2020
Maintains: Outperform
Price Target: $170 → $180
Current: $126.44
Upside: +42.36%
Merck & Co.
Apr 1, 2020
Maintains: Sector Perform
Price Target: $92 → $89
Current: $86.60
Upside: +2.77%
Amneal Pharmaceuticals
Jan 2, 2020
Maintains: Sector Perform
Price Target: $3 → $4
Current: $8.17
Upside: -51.04%
OptiNose
Nov 7, 2017
Initiates: Outperform
Price Target: $495
Current: $9.16
Upside: +5,303.93%
Teva Pharmaceutical Industries
Aug 4, 2017
Downgrades: Underperform
Price Target: n/a
Current: $15.29
Upside: -
Pacira BioSciences
Apr 13, 2017
Initiates: Outperform
Price Target: $58
Current: $24.89
Upside: +133.03%